Table 3: Comparison of the specificity of anti-MSP1-19 antibodies (defined as the proportion of sera binding to variant antigens representing putative ‘inhibitory’ specificities) by sex, age, village of residence, bed net use and sickle cell status.
|
|
Prevalence of ‘inhibitory’ phenotype antibodies |
|||||||||
|
M3X (N = 52) |
M4X34 (N = 52) |
M4X15 (N = 52) |
||||||||
|
n (%) |
c2 |
P |
n (%) |
c2 |
P |
n (%) |
c2 |
P |
||
|
Sex |
M (N = 52) |
13 (25) |
13.71 |
< 0.001 |
13 (25) |
13.71 |
< 0.001 |
13 (25) |
13.71 |
< 0.001 |
|
F (N = 66) |
39 (59) |
|
|
39 (59) |
|
|
39 (59) |
|
|
|
|
Age (yrs) |
7-9 (N = 19) |
19 (12) |
2.88 |
0.3 |
6 (12) |
2.88 |
0.3 |
6 (12) |
2.88 |
0.3 |
|
10-12 (N = 64) |
27 (52) |
|
|
27 (52) |
|
|
27 (52) |
|
|
|
|
13-16 (N = 35) |
19 (37) |
|
|
19 (37) |
|
|
19 (37) |
|
|
|
|
Village Other |
(N = 23) |
7 (30) |
3.52 |
0.3 |
7 (30) |
3.52 |
0.3 |
7 (30) |
3.52 |
0.3 |
|
Atopi |
(N = 65) |
30 (46) |
|
|
30 (46) |
|
|
30 (46) |
|
|
|
Ayera |
(N = 13) |
8 (61) |
|
|
8 (61) |
|
|
8 (61) |
|
|
|
Baraboce |
(N = 17) |
7 (41) |
|
|
7 (41) |
|
|
7 (41) |
|
|
|
Normal spleen |
(N = 98) |
41 (42) |
1.17 |
0.3 |
41 (42) |
1.17 |
0.3 |
41 (42) |
1.17 |
0.3 |
|
Enlarged spleen |
(N = 20) |
11 (55) |
|
|
11 (55) |
|
|
11 (55) |
|
|
|
HbAA (N = 164) |
36 (43) |
0 |
1 |
36 (43) |
0 |
1 |
36 (43) |
0 |
1 |
|
|
HbAS (N = 59) |
14 (44) |
|
|
14 (44) |
|
|
14 (44) |
|
|
|
|
Bed net use |
No (N = 101) |
45 (45) |
0.07 |
0.8 |
45 (45) |
0.07 |
0.8 |
45 (45) |
0.07 |
0.8 |
|
Yes (N = 17) |
7 (41) |
|
|
7 (41) |
|
|
7 (41) |
|
|
|
Apart from village (df = 3) all tests were for 1 degree of freedom. All values in bold represent statistically significant differences i.e. P < 0.05. (HbAA = non-sickle cell trait; HbAS = children with sickle cell trait).